Literature DB >> 16731853

The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.

David J Baker1, Paul L Greenhaff, Alan MacInnes, James A Timmons.   

Abstract

Glycogen phosphorylase inhibition represents a promising strategy to suppress inappropriate hepatic glucose output, while muscle glycogen is a major source of fuel during contraction. Glycogen phosphorylase inhibitors (GPi) currently being investigated for the treatment of type 2 diabetes do not demonstrate hepatic versus muscle glycogen phosphorylase isoform selectivity and may therefore impair patient aerobic exercise capabilities. Skeletal muscle energy metabolism and function are not impaired by GPi during high-intensity contraction in rat skeletal muscle; however, it is unknown whether glycogen phosphorylase inhibitors would impair function during prolonged lower-intensity contraction. Utilizing a novel red cell-perfused rodent gastrocnemius-plantaris-soleus system, muscle was pretreated for 60 min with either 3 micromol/l free drug GPi (n=8) or vehicle control (n=7). During 60 min of aerobic contraction, GPi treatment resulted in approximately 35% greater fatigue. Muscle glycogen phosphorylase a form (P<0.01) and maximal activity (P<0.01) were reduced in the GPi group, and postcontraction glycogen (121.8 +/- 16.1 vs. 168.3 +/- 8.5 mmol/kg dry muscle, P<0.05) was greater. Furthermore, lower muscle lactate efflux and glucose uptake (P<0.01), yet higher muscle Vo(2), support the conclusion that carbohydrate utilization was impaired during contraction. Our data provide new confirmation that muscle glycogen plays an essential role during submaximal contraction. Given the critical role of exercise prescription in the treatment of type 2 diabetes, it will be important to monitor endurance capacity during the clinical evaluation of nonselective GPi. Alternatively, greater effort should be devoted toward the discovery of hepatic-selective GPi, hepatic-specific drug delivery strategies, and/or alternative strategies for controlling excess hepatic glucose production in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731853     DOI: 10.2337/db05-1687

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  9 in total

1.  The N-terminus of glycogen phosphorylase b is not required for activation by adenosine 5'-monophosphate.

Authors:  Andrew N Bigley; Gregory D Reinhart
Journal:  Biochemistry       Date:  2010-06-15       Impact factor: 3.162

2.  Glycogen phosphorylase inhibition improves beta cell function.

Authors:  Lilla Nagy; Judit Márton; András Vida; Gréta Kis; Éva Bokor; Sándor Kun; Mónika Gönczi; Tibor Docsa; Attila Tóth; Miklós Antal; Pál Gergely; Balázs Csóka; Pal Pacher; László Somsák; Péter Bai
Journal:  Br J Pharmacol       Date:  2017-06-18       Impact factor: 8.739

3.  PPARdelta agonism inhibits skeletal muscle PDC activity, mitochondrial ATP production and force generation during prolonged contraction.

Authors:  Dumitru Constantin-Teodosiu; David J Baker; Despina Constantin; Paul L Greenhaff
Journal:  J Physiol       Date:  2008-11-10       Impact factor: 5.182

4.  Restoration of hepatic glycogen deposition reduces hyperglycaemia, hyperphagia and gluconeogenic enzymes in a streptozotocin-induced model of diabetes in rats.

Authors:  S Ros; M García-Rocha; J Calbó; J J Guinovart
Journal:  Diabetologia       Date:  2011-08-03       Impact factor: 10.122

5.  The many metabolic sources of acetyl-CoA to support histone acetylation and influence cancer progression.

Authors:  Olivier Feron
Journal:  Ann Transl Med       Date:  2019-12

6.  Hepatic overexpression of a constitutively active form of liver glycogen synthase improves glucose homeostasis.

Authors:  Susana Ros; Delia Zafra; Jordi Valles-Ortega; Mar García-Rocha; Stephen Forrow; Jorge Domínguez; Joaquim Calbó; Joan J Guinovart
Journal:  J Biol Chem       Date:  2010-09-14       Impact factor: 5.157

7.  An assessment of the in vivo efficacy of the glycogen phosphorylase inhibitor GPi688 in rat models of hyperglycaemia.

Authors:  S M Poucher; S Freeman; S J G Loxham; G Convey; J B Bartlett; J De Schoolmeester; J Teague; M Walker; A V Turnbull; A D Charles; F Carey; S Berg
Journal:  Br J Pharmacol       Date:  2007-10-15       Impact factor: 8.739

8.  Novel Liver-targeted conjugates of Glycogen Phosphorylase Inhibitor PSN-357 for the Treatment of Diabetes: Design, Synthesis, Pharmacokinetic and Pharmacological Evaluations.

Authors:  Liying Zhang; Chengjun Song; Guangxin Miao; Lianzhi Zhao; Zhiwei Yan; Jing Li; Youde Wang
Journal:  Sci Rep       Date:  2017-02-22       Impact factor: 4.379

9.  Glycogen phosphorylase inhibitor N-(3,5-dimethyl-Benzoyl)-N'-(β-D-glucopyranosyl)urea improves glucose tolerance under normoglycemic and diabetic conditions and rearranges hepatic metabolism.

Authors:  Lilla Nagy; Tibor Docsa; Magdolna Szántó; Attila Brunyánszki; Csaba Hegedűs; Judit Márton; Bálint Kónya; László Virág; László Somsák; Pál Gergely; Péter Bai
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.